Latest minimal residual disease Stories
Genomic service detects 30 gene mutations to aid in the diagnosis, prognosis, monitoring and treatment selection for several myeloid neoplasms MADISON, N.J., May 4, 2015 /PRNewswire/
SEATTLE, April 28, 2015 /PRNewswire/ -- Adaptive Biotechnologies today announced the recent publication of a study conducted with researchers at The University of Texas MD Anderson Cancer Center
SEATTLE, April 22, 2015 /PRNewswire/ -- Adaptive Biotechnologies today announced the recent publication of a study demonstrating that analysis of circulating tumor DNA (ctDNA) using the company's
SEATTLE, April 15, 2015 /PRNewswire/ -- Adaptive Biotechnologies, the company pioneering Next Generation Sequencing (NGS) applications for cancer immunology, and its collaborators will present
NESS ZIONA, Israel, March 16, 2015 /PRNewswire/ -- - Recognition of the unmet medical need and high therapeutic potential of ImMucin in Multiple
Deal Expected to Expedite the Development and Commercialization of Immunosequencing Applications SEATTLE, Jan.
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant THOUSAND OAKS, Calif., Dec.
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia NORTH CHICAGO, Ill., Dec.
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle THOUSAND OAKS, Calif., Dec.
- The parings of haberdine; also, any kind of fragments.